Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 8/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | TK2 | O00142 | 6/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807989 | 0.71 | CYP2C9 (0.37) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL21808098 | 0.71 | CYP2C9 (0.37) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL28791230 | 0.68 | KIF11 (0.47) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL2207349 | 0.67 | KIF11 (0.39) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL1092597 | 0.67 | KIF11 (0.54) | CYP2C9TSHRCYP2C19KIF11TK1 | |
| SCHEMBL21807990 | 0.65 | ELANE (0.36) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL9865376 | 0.64 | KIF11 (0.56) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| Ammonia Solution, Strong SCHEMBL7560279 | 0.64 | KIF11 (0.50) | CYP2C9TSHRCYP2C19KIF11TK1 | |
| SCHEMBL11275984 | 0.64 | KIF11 (0.74) | CYP2C9ALOX15TSHRCYP2C19KIF11 | |
| SCHEMBL22091459 | 0.64 | KIF11 (0.39) | CYP2C9ALOX15TSHRCYP2C19KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113544122-A | Cyclopentyl nucleoside analogs as antiviral agents | 詹森生物制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3894395-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020121123-A2 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-8569490-B2 | Intermediate and process for preparing entecavir using same | HANMI SCIENCE CO., LTD (KR) | 2013-10-29 | — | — | US | disclosed |
| EP-2382217-B1 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | HANMI SCIENCE CO LTD (KR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2382217-A2 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | Hanmi Holdings Co., Ltd. (KR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110251387-A1 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | HANMI HOLDINGS CO., LTD. (KR) | 2011-10-13 | — | — | US | disclosed |
| WO-2010074534-A2 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | HANMI PHARM. CO., LTD. (KR) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251387-A1 | NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME | ENTPD5, ENTPD1, SAMHD1 | CYP2C9 482/4885ALOX15 2297/4885TSHR 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.